Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mEdICARE: Aflibercept vs PRP in Proliferative Diabetic Retinopathy
NCT02151695Phase 2Completed
- Sponsor
- CHU de Poitiers
- Start
- May 2015
- Primary completion
- Oct 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in proliferative diabetic retinopathy (PDR), sponsored by CHU de Poitiers. Started May 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT02151695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151695.